Lisa Ledoux, NP
Acute Care · Springfield, MANPI 1922520972
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 275 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 275 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$797
- Pfizer$736
- AstraZeneca$434
- Amgen$427
- Boehringer Ingelheim$325
- E.r. Squibb & Sons, L.L.C.$315
- plus $3K from 28 others
What the payments were for
- Food & beverage$5,536100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 42 | $797 |
| Pfizer | 40 | $736 |
| AstraZeneca(2 entities) | 17 | $434 |
| Amgen | 23 | $427 |
| Boehringer Ingelheim | 16 | $325 |
| E.r. Squibb & Sons, L.L.C. | 18 | $315 |
| Novartis | 16 | $273 |
| Merck | 14 | $253 |
| Harmony Biosciences LLC | 10 | $249 |
| Novo Nordisk | 10 | $214 |
| Kiniksa Pharmaceuticals International, PLC | 9 | $204 |
| Bridgebio Pharma, Inc. | 8 | $191 |
| GSK | 9 | $168 |
| Actelion Pharmaceuticals US, Inc. | 5 | $120 |
| Kiniksa Pharmaceuticals, Ltd. | 6 | $115 |
| AbbVie | 1 | $110 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $65 |
| Abbott | 3 | $60 |
| Regeneron Healthcare Solutions, Inc. | 4 | $58 |
| Amarin Pharma, Inc. | 3 | $51 |
| Heartflow, Inc. | 2 | $47 |
| Alnylam Pharmaceuticals Inc. | 2 | $43 |
| Sanofi-aventis U.S. LLC | 1 | $34 |
| Altathera Pharmaceuticals LLC | 2 | $34 |
| Verona Pharma, Inc. | 1 | $31 |
| United Therapeutics Corporation | 1 | $28 |
| Lantheus Medical Imaging, Inc. | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $20 |
| Boston Scientific | 1 | $18 |
| Bayer | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,536 in reported general payments places this provider in the 95th percentile of 307 acute care providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 175 | $227,804 |
| XareltoRivaroxaban | 59 | $64,416 |
| EntrestoSacubitril/Valsartan | 25 | $30,781 |
| Repatha SureclickEvolocumab | 18 | $21,759 |
| JardianceEmpagliflozin | 23 | $15,376 |
| BrilintaTicagrelor | 16 | $10,919 |
| Metoprolol Succinate | 218 | $3,618 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 56 | $3,226 |
| Rosuvastatin Calcium | 70 | $2,794 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $2,157 |
| Atorvastatin Calcium | 81 | $1,614 |
| Flecainide Acetate | 28 | $1,322 |
| Amlodipine Besylate | 124 | $1,190 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 55 | $1,132 |
| Ezetimibe | 28 | $1,112 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $736 | $227,804175 claims |
| Johnson & JohnsonXarelto | $797 | $64,41659 claims |
| NovartisEntresto | $273 | $30,78125 claims |
| Boehringer IngelheimJardiance | $325 | $15,37623 claims |
| AstraZenecaBrilinta | $434 | $10,91916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 307 acute care providers in Massachusetts.
Other acute care in Springfield
- John-Michael CyczSpringfield$4K
- Shawn SelbySpringfield$3K
- Susan LattanziSpringfield$3K
- Nicole StrieterSpringfield$2K
- Janeena IeraciSpringfield$1K
- Bridgid JosephBoston$110K
- Pamela CalareseBoston$106K
- Kimberly GuiboneBoston$86K
- Audrey RoseWoburn$58K
- Danielle BeaulieuWest Springfield$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.